|

Anti-HER2/HER3 Dendritic Cell Vaccine Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Anti-HER2/3 DC Vaccine, Anti-HER2/3 Dendritic Cell Vaccine

Pipeline

Phase 2: 1

Top Sponsors

  • Roswell Park Cancer Institute1

Indications

  • Metastatic Triple-Negative Breast Carcinoma1
  • Prognostic Stage IV Breast Cancer AJCC v81
  • Metastatic Malignant Neoplasm in the Brain1
  • Anatomic Stage IV Breast Cancer AJCC v81
  • Breast Cancer1

Tampa, Florida1 trial

Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

Moffitt Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.